Navigation Links
InterMune Sells Danoprevir Rights to Roche for $175 Million
Date:10/6/2010

BRISBANE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.  In connection with this transaction, the collaboration agreement that InterMune and Roche entered into in October 2006 has been terminated.  In addition, the companies are actively exploring ways to continue their ongoing work together on other HCV research programs.  InterMune noted that as a result of this transaction, the company will make no further investment in danoprevir and that, including net proceeds from the transaction, it currently expects to have a cash balance of approximately $290 million at the end of 2010.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "After conducting a careful review of our strategy and financial position, we have decided to divest our rights to danoprevir to Roche.  This transaction provides a very substantial non-dilutive cash infusion that allows us to continue to independently and aggressively pursue the registration and commercialization of pirfenidone in the US and EU, and eliminates our obligation to make significant ongoing investments related to the further development and commercialization of danoprevir.  We are now in a very strong financial position that provides us with the resources and flexibility to maximize the value of pirfenidone, our largest and nearest-term value creation opportunity."

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss the transaction.  Interested investors and others may participate in the conference call by dialing 866-408-9480 (U.S.) or 706-643-9223 (international), con
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at 2010 Citi Health Care Conference
2. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
3. InterMune to Release First Quarter Financial Results on April 29
4. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
5. InterMune Announces Proposed Public Offering of Common Stock
6. InterMune to Release Third Quarter Financial Results on November 5
7. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
10. InterMune to Release Second Quarter Financial Results on August 6
11. InterMune to Present at Goldman Sachs Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/30/2014)... The Global and China Electrical ... study on the current state of the Electrical ... The report provides a basic overview of the ... Global market analysis and Chinese domestic market analysis ... trends and competitive landscape of the market. A ...
(Date:8/29/2014)... based on electrons, but one of the most promising ... circuits based on light (photons) instead of electrons. First, ... stream of single photons and control their direction. Researchers ... to achieve this control, but now scientists at the ... stream of photons emitted one at a time and ...
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... of Multi-Use Clearance for Axxent(R), System ... Radiation Therapy, SUNNYVALE, Calif., May 21 ... from the U.S. Food & Drug Administration,(FDA) for ... System for the treatment of endometrial cancer. Previously,cleared ...
... Co., Ltd. announced today,that it has entered into an ... a German biotechnology company focusing on research into,antibodies for ... 100 percent of the stock and make a,one-time payment ... Closure of the transaction is subject to clearance under ...
... world converge on Regenesis, SCOTTSDALE, Ariz., May ... that markets the Provant(R) Wound Therapy,System, announced today ... purpose is to guide advanced scientific investigations into ... and further,application of Regenesis, platform technology to clinical ...
Cached Biology Technology:FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 2FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 3FDA Clears New Applicators for Endometrial Cancer Treatment With Xoft's Axxent(R) Electronic Brachytherapy System 4Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3
(Date:9/2/2014)... in Taiyuan, China, have substantially improved the health of ... reduction in costs associated with loss of life and ... the Columbia Center for Children,s Environmental Health (CCCEH) at ... University, the Center of Diseases Control and Prevention of ... Health. , The study is the first to document ...
(Date:9/2/2014)... of lithographic limestone is well known as a ... that area (for example, Archaeopteryx). Now, for the ... the French equivalent of these outcrops - discoveries ... known water treader. , Despite the abundance of ... have been obtained from the Late Kimmeridgian equivalents ...
(Date:9/2/2014)... done in by it. New research at Rockefeller University ... gap in mice with very similar genetic backgrounds ... the development of psychiatric disorders such as anxiety and ... as it goes through its life. And we suspect ... genes, and as a result, affect an animal,s susceptibility ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... Cheryl Hayashi, a biologist at UC Riverside and a national ... a $500,000 MacArthur Fellowship, one of the most prestigious awards ... MacArthur Fellows for 2007 named by the John D. and ... award, the MacArthur Fellowship is a no strings attached grant ...
... help policy makers to estimate the consequences of various ... much toll must be charged for the desired policy ... all travellers or maximising the toll incomes (revenues). Based ... the impacts on road congestion and the total toll ...
... antimicrobials bind and thereby get inactivated in the mucus ... may have found a way to help cystic fibrosis ... this work has potential as a therapeutic strategy against ... professor of materials science and engineering, of physics, and ...
Cached Biology News:UC Riverside biologist receives prestigious MacArthur Fellowship 2UC Riverside biologist receives prestigious MacArthur Fellowship 3Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials 2
...
... Ferrofluid products perform optimally when ... Systems MagCellect Magnet. To accommodate ... iron boron permanent magnet holds ... mm test tubes or two ...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: